FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

BACKGROUND: ALM201 is a therapeutic peptide derived from FKBPL that has previously undergone preclinical and clinical development for oncology indications and has completed a Phase 1a clinical trial in ovarian cancer patients and other advanced solid tumours. METHODS: In vitro, cancer stem cell (CSC...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: Annett, Stephanie, Moore, Gillian, Short, Amy, Marshall, Andrea, McCrudden, Cian, Yakkundi, Anita, Das, Sudipto, McCluggage, W. Glenn, Nelson, Laura, Harley, Ian, Moustafa, Nermeen, Kennedy, Catherine J., deFazio, Anna, Brand, Alison, Sharma, Raghwa, Brennan, Donal, O’Toole, Sharon, O’Leary, John, Bates, Mark, O’Riain, Ciarán, O’Connor, Darran, Furlong, Fiona, McCarthy, Helen, Kissenpfennig, Adrien, McClements, Lana, Robson, Tracy
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7000737/
https://ncbi.nlm.nih.gov/pubmed/31772325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0649-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares